IDenta Corp. (IDTA)
USD 0.32
(0.0%)
USD 0.32
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 71.58 Thousand USD | -125.62% |
| 2022 | 199.56 Thousand USD | -37.09% |
| 2021 | 233.57 Thousand USD | -36.34% |
| 2020 | 366.92 Thousand USD | 227.4% |
| 2019 | 112.2 Thousand USD | -27.8% |
| 2018 | 156.32 Thousand USD | 208.42% |
| 2017 | -159.19 Thousand USD | 57.84% |
| 2016 | -339.58 Thousand USD | -0.89% |
| 2015 | -336.58 Thousand USD | 41.4% |
| 2014 | -574.38 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 60.13 Thousand USD | -59.53% |
| 2024 Q1 | 181.61 Thousand USD | 21.88% |
| 2023 FY | - USD | -125.62% |
| 2023 Q4 | 127.95 Thousand USD | 486.09% |
| 2023 Q3 | -33.14 Thousand USD | 53.87% |
| 2023 Q1 | -40.42 Thousand USD | -122.3% |
| 2023 Q2 | -71.83 Thousand USD | -77.72% |
| 2022 Q2 | 22.46 Thousand USD | 140.46% |
| 2022 FY | - USD | -37.09% |
| 2022 Q4 | 181.28 Thousand USD | 329.54% |
| 2022 Q3 | 42.2 Thousand USD | 87.85% |
| 2022 Q1 | -55.52 Thousand USD | -186.75% |
| 2021 Q3 | -2614.00 USD | -101.95% |
| 2021 Q2 | 133.96 Thousand USD | 71.07% |
| 2021 FY | - USD | -36.34% |
| 2021 Q4 | 64 Thousand USD | 2548.47% |
| 2021 Q1 | 78.31 Thousand USD | 210.3% |
| 2020 Q4 | -71 Thousand USD | -126.43% |
| 2020 FY | - USD | 227.4% |
| 2020 Q1 | 74.75 Thousand USD | 1195.14% |
| 2020 Q2 | 104.33 Thousand USD | 39.57% |
| 2020 Q3 | 268.63 Thousand USD | 157.48% |
| 2019 Q3 | 61.45 Thousand USD | 33.46% |
| 2019 Q1 | 8168.00 USD | -84.72% |
| 2019 FY | - USD | -27.8% |
| 2019 Q4 | -6826.00 USD | -111.11% |
| 2019 Q2 | 46.04 Thousand USD | 463.7% |
| 2018 Q3 | 101.77 Thousand USD | 1900.65% |
| 2018 FY | - USD | 208.42% |
| 2018 Q4 | 53.45 Thousand USD | -47.48% |
| 2018 Q2 | 5087.00 USD | -66.13% |
| 2018 Q1 | 15.02 Thousand USD | 130.33% |
| 2017 FY | - USD | 57.84% |
| 2017 Q1 | -5123.00 USD | 0.0% |
| 2017 Q2 | -55.86 Thousand USD | -990.4% |
| 2017 Q3 | -48.24 Thousand USD | 13.64% |
| 2017 Q4 | -49.52 Thousand USD | -2.66% |
| 2016 FY | - USD | -0.89% |
| 2015 FY | - USD | 41.4% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 106.155% |
| Arrayit Corporation | -3.07 Million USD | 102.326% |
| Atlantic International Corp. | -5.38 Million USD | 101.328% |
| Biocept, Inc. | -30.24 Million USD | 100.237% |
| Bioqual, Inc. | 3.03 Million USD | 97.639% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 109.452% |
| DermTech, Inc. | -97.89 Million USD | 100.073% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 99.998% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 100.354% |
| iMD Companies, Inc. | -154.65 Thousand USD | 146.287% |
| Interpace Biosciences, Inc. | 3.83 Million USD | 98.134% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -85.027% |
| InVitro International | 6680.00 USD | -971.662% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 101.317% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 689.97% |
| Medical Imaging Corp. | -896.74 Thousand USD | 107.983% |
| NovelStem International Corp. | -3.78 Million USD | 101.891% |
| Optigenex Inc. | -1.18 Million USD | 106.032% |
| PharmChem, Inc. | 1.05 Million USD | 93.207% |
| Proteome Sciences plc | -1.13 Million USD | 106.296% |
| Response Genetics, Inc | -19.66 Million USD | 100.364% |
| Rennova Health, Inc. | -234.81 Thousand USD | 130.487% |
| RushNet, Inc. | -614.85 Thousand USD | 111.643% |
| ScreenPro Security Inc. | -3.43 Million USD | 102.084% |
| Stella Diagnostics Inc. | -5.7 Million USD | 101.254% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 100.697% |
| Todos Medical Ltd. | -9.39 Million USD | 100.762% |